BC Innovations | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2); MLL-AF9 fusion oncogene

Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting MTHFD2 could help treat AML. In human AML cell lines, shRNA targeting MTHFD2 decreased proliferation and colony formation compared with scrambled shRNA....
Items per page:
1 - 1 of 1